Skip to main
GERN
GERN logo

Geron (GERN) Stock Forecast & Price Target

Geron (GERN) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 50%
Buy 33%
Hold 11%
Sell 0%
Strong Sell 6%

Bulls say

Geron Corp’s stock outlook appears positive due to the European Commission's recent approval of Rytelo (imetelstat) for treating low-risk myelodysplastic syndrome (LR-MDS), which is anticipated to significantly enhance revenue streams starting in 2026. The company's strategic plans to educate healthcare providers about Rytelo, coupled with the strong prescriber feedback indicating its effectiveness, are expected to drive sales growth in both first-line and second-line treatment settings. Furthermore, potential approval for relapsed/refractory myelofibrosis could further double the commercial opportunity for Rytelo, solidifying Geron's position in the oncology market.

Bears say

Geron Corp's recent financial performance indicates a concerning trend, with management reporting flat revenue growth due to a slowdown in the Rytelo launch for lower-risk myelodysplastic syndromes. The company's reliance on 3rd-line patients for the majority of Rytelo prescriptions, coupled with disappointing uptake among 2nd-line patients, suggests challenges in expanding market penetration. Additionally, lowered peak sales expectations for Rytelo, now projected at $1.0 billion compared to previous estimates of $1.2 billion, highlight the increasing risks associated with the company’s clinical programs and competitive pressures in the oncology market.

Geron (GERN) has been analyzed by 18 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 33% recommend Buy, 11% suggest Holding, 0% advise Selling, and 6% predict a Strong Sell.

This aggregate rating is based on analysts' research of Geron and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Geron (GERN) Forecast

Analysts have given Geron (GERN) a Buy based on their latest research and market trends.

According to 18 analysts, Geron (GERN) has a Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.01, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.01, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Geron (GERN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.